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BACKGROUND. Dysplasia in Barrett esophagus is a premalignant condition that is
associated with an increased risk of developing esophageal adenocarcinoma. Un-
fortunately, clinical investigation aimed at prevention of progression to malignant
disease has been hampered by the variable prevalence of dysplasia reported in the
literature. The objective of the current study was to more accurately determine the
prevalence of dysplasia among individuals with Barrett esophagus who would be
available for enrollment in a chemoprevention trial.
METHODS. The pathology archives of 3 institutions were reviewed over a 5-year
period for all reports of diagnoses of Barrett esophagus. Surgical cases, malignan-
cies, and duplicate or referral cases were excluded from the analysis.
RESULTS. A total of 790 cases of Barrett esophagus were identified. Of these, 37
(4.7%) were cases of low-grade dysplasia (LGD), and 20 (2.5%) were cases of
high-grade dysplasia. The University of Michigan Medical Center (Ann Arbor, MI)
diagnosed 18 cases of LGD, Henry Ford Hospital (Detroit, MI) diagnosed 15 cases
of LGD, and Brigham and Women’s Hospital (Boston, MA) diagnosed 4 cases of
LGD in patients with Barrett esophagus over the 5-year study period.
CONCLUSIONS. The confirmed low prevalence of cases of LGD will affect the design
of future clinical trials of chemopreventive interventions for Barrett esophagus.
Cancer 2004;100:1622–7. © 2004 American Cancer Society.
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In patients with Barrett esophagus or Barrett mucosa, metaplasticcolumnar epithelium replaces the normal squamous epithelium in
the distal esophagus. This condition develops in approximately 10 –
15% of patients with chronic gastroesophageal reflux.1,2 Barrett
esophagus is the major recognized risk factor for esophageal adeno-
carcinoma, and patients have a 30 – 40-fold increased risk of develop-
ing malignant disease compared with the general population.3,4
The incidence of adenocarcinoma of the esophagus has been
increasing steadily in the United States for the last 20 years, with the
incidence in white males growing by  350% over that time period.5
Aggressive medical management of acid reflux, lifestyle modifica-
tions, laser ablation, and endoscopic surveillance have been recom-
mended for many patients with Barrett esophagus.6 – 8 Whether these
interventions are cost-effective or reduce mortality from esophageal
cancer remains controversial.9
Dysplasia in Barrett esophagus is an intraepithelial neoplasia and
the primary predictor of progression to adenocarcinoma.10 High-
grade dysplasia (HGD) in Barrett esophagus frequently undergoes
malignant transformation and is associated with a high rate of occult
malignancy. For this reason, many patients with HGD undergo
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esophageal resection.11,12 Limited data are available
for elucidating the rate at which low-grade dysplasia
(LGD) progresses to HGD or carcinoma. Some studies
suggest that the rate ranges from 10% to 30% over 5
years.13–16
Due to the increased risk of malignant disease and
the lack of good treatment options for LGD in Barrett
esophagus, a randomized chemoprevention trial was
recently performed in which difluoromethylornithine
(DFMO) was given to individuals with Barrett esoph-
agus who either had LGD or did not exhibit dyspla-
sia.17 In that study, in which a single pathologist re-
viewed every case, the number of patients identified
and enrolled was exceedingly small (LGD: n  2; neg-
ative for dysplasia: n  77). This finding was unex-
pected, as the prevalence of dysplasia reported in the
literature is highly variable.13,18 –25 One study reported
LGD in as many as 70.8% of patients with Barrett
esophagus.18 This variability in prevalence rates rep-
resents a challenge in designing and implementing
randomized chemoprevention studies. In the current
study, we searched within a small multiinstitutional
consortium to retrospectively identify individuals with
dysplasia in Barrett esophagus who would be available
for enrollment in a chemoprevention trial.
MATERIALS AND METHODS
Study Design and Population
A retrospective review of the pathology archives of the
University of Michigan (Ann Arbor, MI), Henry Ford
Hospital (Detroit, MI), and Brigham and Women’s
Hospital (Boston, MA) over a 5-year period was per-
formed to identify all cases of Barrett esophagus. Re-
ports of specimens that were obtained from biopsies
and resections above the gastroesophageal junction
and reported as either intestinal-type Barrett esopha-
gus, specialized-type Barrett esophagus, or special-
ized-type columnar epithelium were included in the
analysis. No pathology specimens or slides were
pulled for review.
After obtaining institutional review board exemp-
tion, pathology reports from the University of Michi-
gan over the period 1995–1999 were reviewed for eli-
gibility. Original identifiers for patients were used
initially to identify duplicate reports. Case numbers
were subsequently assigned, and all identifiers were
then removed. If there were duplicate reports for any
one case, then the most advanced diagnosis was used.
When there were multiple reports with the same di-
agnosis, the earliest diagnosis was used. The data re-
corded from each report included the type of Barrett
esophagus (negative for dysplasia, indefinite for dys-
plasia, LGD, and HGD), age, gender, whether the spec-
imen was obtained after a biopsy or a resection, and
the year of the report. Additional information included
the pathologist to whom the case was referred, the
physician who wrote the official report, the five-digit
accession number, and the hospital registration num-
ber. Reports with any findings of cancer, surgically
resected cases, and referral cases were removed before
analysis.
Data from Henry Ford Hospital included the pe-
riod between 1996 and the first 3 months of 2000. Data
from Brigham and Women’s Hospital were collected
for the period 1995–1999. Data were collected and
handled at both institutions in the same manner as at
the University of Michigan.
Cases of Barrett esophagus were summarized by
degree of dysplasia, institution of origin, and year of
diagnosis. Differences among institutions in the pro-
portion of cases by degree of dysplasia were tested
using the standard Pearson chi-square statistic. Com-
parisons of case characteristics between types of dys-
plasia were made using the two-sample t test and the
chi-square statistic when appropriate. Two-sided P
values  0.05 were considered to be statistically sig-
nificant.
Definition of Outcome
Barrett esophagus was diagnosed if metaplastic co-
lumnar epithelium was observed in biopsy specimens
obtained from the tubular esophagus above the gas-
troesophageal junction. Dysplasia was defined as neo-
plastic epithelium that was not invasive. Cytologic
changes included nuclear enlargement, hyperchrom-
atism, pleomorphism and stratification, atypical-ap-
pearing mitoses, and loss of cytoplasmic maturation.
Architectural changes included crowding of tubules
and/or villiform surfaces.26 LGD was characterized by
these changes occurring with a relatively low level of
intensity and by more closely caricatured nonneoplas-
tic epithelium, whereas HGD was characterized by
more intense changes. If the biopsy specimen had
morphologic changes that were not clearly dysplastic
but also not clearly reactive, then the biopsy specimen
was considered to be indefinite for dysplasia.
RESULTS
Among the 3 institutions involved in the study, 790
cases of Barrett esophagus met the study criteria. Case
characteristics are shown in Table 1. Seventy percent
of the cases who were negative for dysplasia were
male, and 30% were female. Males accounted for 78%
of LGD cases and 90% of HGD cases. The mean age of
cases who were negative for dysplasia was 57.8  13.8
years, the mean age of cases with LGD was 62.9  12.7
years, and the mean age of cases with HGD was 67.3
 12.8 years. The mean age of cases with HGD was
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statistically different from the mean age of cases who
were negative for dysplasia (P  0.004).
Of the 790 cases identified, 360 were from the
University of Michigan, 191 were from Henry Ford
Hospital, and 239 were from Brigham and Women’s
Hospital (Table 2). When all institutions were com-
bined, negative for dysplasia accounted for 686 cases,
indefinite for dysplasia accounted for 47 cases, LGD
accounted for 37 cases, and HGD accounted for 20
cases. At the University of Michigan, Henry Ford Hos-
pital, and Brigham and Women’s Hospital, LGD rep-
resented 5.0%, 7.9%, and 1.7% of all Barrett esophagus
cases, respectively. The difference between Henry
Ford Hospital and Brigham and Women’s Hospital
was statistically significant (P  0.004). None of the
rates for other dysplasia types were statistically differ-
ent across institutions.
Table 3 shows the distribution of the types of
Barrett esophagus by year. For all institutions, the
number of cases that were negative for dysplasia
ranged from 118 to 174 per year, the number of cases
that were indefinite for dysplasia ranged from 8 to 11
per year, the number of LGD cases ranged from 5 to 12
per year, and the number of HGD cases ranged from 2
to 6 per year.
DISCUSSION
The current multiinstitutional review supports the
finding that few individuals with dysplasia in Barrett
esophagus are available for enrollment in chemopre-
vention trials.17 Dysplasia in Barrett esophagus is a
premalignant condition that has been the focus of
attention for esophageal adenocarcinoma prevention
strategies and remains the primary predictor of ma-
lignant progression.10 However, the limited number of
individuals with LGD has ramifications for those com-
mitted to the clinical study of Barrett esophagus.
Variable rates of dysplasia in the literature have
TABLE 1













Male 476 (69) 28 (60) 29 (78) 18 (90) 551 (70)
Female 210 (31) 19 (40) 8 (22) 2 (10) 239 (30)
Agea 57.8  13.8 62.2  11.4 62.9  12.7 67.3  12.8b
a Mean age in years  standard deviation.
b P  0.004 for comparison with negative for dysplasia group.
TABLE 2








No. (%) No. (%) No. (%) No. (%)
Dysplasia
Negative 163 (85.3) 303 (84.2) 220 (92.3) 686 (86.8)
Indefinite 11 (5.8) 27 (7.5) 9 (3.8) 47 (5.9)
Low-grade 15 (7.9)b 18 (5.0) 4 (1.7) 37 (4.7)
High-grade 2 (1.0) 12 (3.3) 6 (2.5) 20 (2.5)
Total 191 360 239 790
a Includes data covering a period of 4 years and 3 months.
b P  0.004 for comparison with low-grade dysplasia group at Brigham and Women’s Hospital.
TABLE 3
Number of Cases of Barrett Esophagus (All Institutions) by Year of
Collection
Pathology Yr 1 Yr 2 Yr 3 Yr 4 Yr 5a
Dysplasia
Negative 136 118 136 174 122
Indefinite 9 11 8 11 8
Low-grade 5 10 5 12 5
High-grade 2 3 3 6 6
Total 152 142 152 203 141
a Data from Henry Ford Hospital covers only the first 3 months of the year.
1624 CANCER April 15, 2004 / Volume 100 / Number 8
made the design of clinical chemoprevention trials
challenging (Table 4).13,18 –25 Several single-institution
studies have attempted to directly measure the prev-
alence and/or incidence of dysplasia in Barrett esoph-
agus.19 –21,24 Those institutions report LGD in
7.9 –25.9% of cases of Barrett esophagus. Gopal et al.22
recently published a prospective multiinstitutional
study that attempted to determine risk factors for dys-
plasia. In that study, LGD was diagnosed in 9.4% of all
Barrett esophagus cases. Although the study con-
ducted by Gopal et al. was multiinstitutional, 75% of
all cases were diagnosed at a Veterans Administration
hospital, and thus the study population is not likely to
have been representative of the population of individ-
uals with Barrett esophagus in the United States. Most
of the reported case series are from surveillance pro-
grams, which can best determine the number of inci-
dent (newly diagnosed) cases of dysplasia. However,
identification of all cases by review of pathology
records mimics clinical trial recruitment and provides
a better measure of prevalent cases and potential par-
ticipants available for chemopreventive interventions.
The current analysis, in which cases were identified by
pathology review, involves an unselected cohort of
cases of LGD in Barrett esophagus diagnosed at three
institutions serving diverse populations.
The variability across studies is primarily a reflec-
tion of problems with the diagnosis of dysplasia. De-
spite attempts at establishing criteria for the diagnosis
of dysplasia in Barrett esophagus in 198827 and at-
tempts at refinement of those criteria in 2001,28 con-
firmation of the diagnosis remains a significant chal-
lenge. Several studies have reported that LGD was not
confirmed in approximately 75% of patients.20,21,23
Even among experienced pathologists, the interob-
server agreement for the diagnosis of LGD is only
50%.27,28 In the current study, more than three pathol-
ogists across the three institutions were involved in
reporting LGD. However, results from our recent mul-
tiinstitutional clinical trial, in which a central pathol-
ogist reviewed all cases, were consistent with the re-
sults of the current analysis (2.6% LGD; unpublished
data). Combining the indefinite for dysplasia and LGD
categories improves the concordance among pathol-
ogists. As a result, some have chosen to combine these
diagnoses when reporting rates.13,24,27 In the current
study, the combined percentage of indefinite/LGD
cases was 10.6%. Diagnostic problems will be lessened
TABLE 4
Long-Term Series of Low-Grade Dysplasia in Barrett Esophagus without Concurrent Malignancy







Hameeteman et al., 198913 Single-institution,
prospective
Unknown (14 yrsc) Yes 50 9 (18.0) Combined percentage of
indefinite and LGD cases:
28.0%
Miros et al., 199124 Single-institution,
prospective
1981–1988 No 81 21 (25.9) Indefinite and LGD cases
combined
Weston et al., 199720 Single-institution,
prospective
Unknown (40 mosd) Yes 152 16 (10.5) Nine of 16 LGD cases not
confirmed on follow-up;
20% incident cases on
small subset
O’Connor et al., 199921 Single-institution,
retrospective
1979–1995 No 136 34 (25.0) Twenty-five LGD cases (73%)
not confirmed on follow-up
Hirota et al., 199919 Single-institution,
prospective
1995–1996 Yes 63 5 (7.9) Incident cases not reported
Reid et al., 200025 Single-institution,
prospective
1983–1998 No 327 43 (13.1) Incident cases not reported
Schnell et al., 200118 Single-institution,
retrospective
1979–2000 No 1057 748 (70.8)
Gopal et al., 200322 Multiinstitutional,
prospective
1994–1998 No 304 29 (9.5) Seventy-five percent of cases
from Veterans
Administration hospitals
Conio et al., 200323 Multiinstitutional,
prospective
1987–1997 Yes 166 40 (24.1) Thirty LGD cases (75%) not
confirmed on follow-up
BE: Barrett esophagus; LGD: low-grade dysplasia.
a Denotes whether pathology was reported as reviewed and/or confirmed by an additional pathologist.
b Percentage of patients who ever had findings of LGD in Barrett esophagus during the specified time period.
c Longest duration of follow-up; dates of surveillance not specified.
d Duration of study period; dates of surveillance not specified.
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by the further development of biomarkers that can
better predict which individuals will experience pro-
gression to invasive malignancy.29 –31 However, until
that time, difficulties with the pathologic diagnosis
will continue to represent a challenge in chemopre-
vention studies.
Variations in environmental influences and risk
groups of Barrett esophagus across the country might
also result in differences in the rates of dysplasia that
are reported. Limited information is provided in other
studies with regard to population characteristics.
However, variation in esophageal adenocarcinoma in-
cidence across the country supports the likelihood of
regional variation in the occurrence of dysplasia.32 In
addition, although the columnar epithelium of Barrett
mucosa can have a distinctive red hue and velvety
texture, dysplasia has no obvious appearance. Thus,
sampling error is prominent due to the requirement of
random biopsies in standard endoscopic proce-
dures.33 Sampling error and spontaneous regression
are likely contributors to the difficulty of confirming
the diagnosis of LGD in surveillance series.20,21,23 More
rigorous biopsy techniques, as used for HGD surveil-
lance,14,33 may lead to more accurate measures of LGD
prevalence, but currently, these techniques are not
used routinely for Barrett esophagus or LGD surveil-
lance.
In the current analysis, we used the most ad-
vanced diagnosis for each individual. Four cases of
LGD were not counted because their diagnoses pre-
ceded more advanced diagnoses (i.e., HGD or malig-
nant disease). Consequently, the number of LGD cases
may have been underestimated to a small degree.
Referral bias is a major concern in reporting preva-
lence estimates in Barrett esophagus, particularly at
large tertiary medical centers. Exclusion of patients
referred from extramural physicians for pathologic re-
view limited referral bias, resulting in a more accurate
reflection of the number of individuals with dysplasia
who would be treated at each institution. Surgical
specimens also were excluded, because many patients
who undergo surgery represent referral cases. These
individuals would also not be available for chemopre-
ventive interventions. However, many individuals
with diagnoses of LGD or indefinite for dysplasia un-
dergo follow-up with community gastroenterologists.
Therefore, the rates reported from tertiary care centers
might not reflect the true prevalence of dysplasia
within a given population.
Poor recruitment rates in chemoprevention trials
underscore the importance of accurately determining
the number of potential participants. The ratio of po-
tential participants screened for enrollment to those
who are actually enrolled varies markedly, ranging
from 7:1 to  100:1.17,34 Our recent randomized effi-
cacy trial for a putative chemoprevention agent (i.e.,
DFMO) required 76 participants per arm to detect a
designed morphologic regression or biomarker mod-
ulation.17 With a screened-to-on-study ratio of 15:1, as
encountered in this study,17 2280 (i.e., 15  152) oth-
erwise eligible participants would be required. Our
intent in performing the current analysis was to de-
termine the recruitment cohort size necessary to study
the efficacy of a chemopreventive intervention in a
randomized design. Due to the documented low rate
of LGD and the poor screened-to-on-study ratio, the
screening of such a population would require the col-
laboration of the bulk of the institutions in the United
States to successfully identify, recruit, and retain the
necessary number of study participants.
We believe that the current analysis estimates the
number of individuals with LGD in Barrett esophagus
who are available for chemoprevention studies more
accurately than do previous reports. Based on our
findings, alternative clinical trial designs will be re-
quired to effectively study chemopreventive interven-
tions for patients with Barrett esophagus.
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